Literature DB >> 18584351

Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.

Lucienne Juillerat-Jeanneret1, Catherine Chapuis Bernasconi, Charlotte Bricod, Solange Gros, Sylviane Trepey, Jean Benhattar, Robert C Janzer.   

Abstract

The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment. The methylation of MGMT promoter and the expression of MGMT and GST were highly heterogeneous in surgical specimens of human glioblastoma and in established human glioblastoma cells under 2-D and 3-D culture conditions, suggesting an intrinsic property of these cells. MGMT and GST expression did not predict the sensitivity of glioblastoma cells to alkylating agents. Combination of alkylating agents with inhibitors of GST disclosed additive effects, suggesting that inhibition of GST should be considered in glioblastoma therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584351     DOI: 10.1080/07357900802072913

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  12 in total

1.  MGMT promoter methylation in non-neoplastic brain.

Authors:  Chih-Yi Hsu; Hsiang-Ling Ho; Yi-Chun Chang-Chien; Yi-Wen Chang; Donald Ming-Tak Ho
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

2.  Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults.

Authors:  Erik Vassella; Istvan Vajtai; Nora Bandi; Marlene Arnold; Verena Kocher; Luigi Mariani
Journal:  J Neurooncol       Date:  2010-12-22       Impact factor: 4.130

Review 3.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

4.  MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Authors:  Fateme Salehi; Bernd W Scheithauer; Johann M Kros; Queenie Lau; Michael Fealey; Dana Erickson; Kalman Kovacs; Eva Horvath; Ricardo V Lloyd
Journal:  J Neurooncol       Date:  2011-02-11       Impact factor: 4.130

5.  Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.

Authors:  Mark G Hamilton; Gloria Roldán; Anthony Magliocco; John B McIntyre; Ian Parney; Jacob C Easaw
Journal:  J Neurooncol       Date:  2010-07-21       Impact factor: 4.130

6.  Glutathione S-Transferases and Cytochrome P450 Enzyme Expression in Patients with Intracranial Tumors: Preliminary Report of 55 Patients.

Authors:  Cahit Kural; Arzu Kaya Kocdogan; Gulcin Güler Şimşek; Serpil Oğuztüzün; Pınar Kaygın; Irmak Yılmaz; Tugbag Bayram; Yusuf Izci
Journal:  Med Princ Pract       Date:  2018-10-15       Impact factor: 1.927

7.  JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.

Authors:  Astrid Weyerbrock; Nadja Osterberg; Nikolaos Psarras; Brunhilde Baumer; Evangelos Kogias; Anna Werres; Stefanie Bette; Joseph E Saavedra; Larry K Keefer; Anna Papazoglou
Journal:  Neurosurgery       Date:  2012-02       Impact factor: 4.654

8.  Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.

Authors:  Chih-Yi Hsu; Hsiang-Ling Ho; Shih-Chieh Lin; Yi-Chun Chang-Chien; Ming-Hsiung Chen; Sanford Ping-Chuan Hsu; Yu-Shu Yen; Wan-You Guo; Donald Ming-Tak Ho
Journal:  J Neurooncol       Date:  2015-01-10       Impact factor: 4.130

9.  Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells.

Authors:  Maria Zeniou; Marie Fève; Samir Mameri; Jihu Dong; Christophe Salomé; Wanyin Chen; Elias A El-Habr; Fanny Bousson; Mohamadou Sy; Julie Obszynski; Alexandre Boh; Pascal Villa; Suzana Assad Kahn; Bruno Didier; Dominique Bagnard; Marie-Pierre Junier; Hervé Chneiweiss; Jacques Haiech; Marcel Hibert; Marie-Claude Kilhoffer
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

10.  Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.

Authors:  J Dunn; A Baborie; F Alam; K Joyce; M Moxham; R Sibson; D Crooks; D Husband; A Shenoy; A Brodbelt; H Wong; T Liloglou; B Haylock; C Walker
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.